NDRA ENDRA Life Sciences
ENDRA Life Sciences earnings company data as of 4:48 AM ET 10/23
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 13 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 14 Aug | EPS | — | 0.06 | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by NDRA's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- None no sales outside a trading plan
- None no planned (10b5-1) sales
No open-market buys or sales on file.
Also filed in the last 12 months, not counted as buying or selling: 7 stock grants.
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13D | — | Filing Doc | |
| 8-K | 1.01,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | QUARTERLY REPORT | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| 8-K | 1.01,5.01,7.01,8.01,9.01 | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 1.01,3.02,8.01,9.01 | Filing Doc | |
| 10-Q | QUARTERLY REPORT | Filing Doc | |
| 8-K | 3.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-K | ANNUAL REPORT | Filing Doc | |
| 8-K | 2.05,7.01,9.01 | Filing Doc | |
| 8-K | 5.02,5.03,5.07,9.01 | Filing Doc | |
| 8-K | 5.02,9.01 | Filing Doc | |
| SCHEDULE 13D | — | Filing Doc | |
| 424B4 | PROSPECTUS | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | QUARTERLY REPORT | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 424B5 | PROSPECTUS SUPPLEMENT | Filing Doc | |
| 8-K | 1.01,9.01 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.